Abstract: Blood pressure (BP) measurements provide information regarding risk factors associated with cardiovascular disease, but only in a specifi c artery. Arterial stiffness (AS) can be determined by measurement of arterial pulse wave velocity (APWV). Separate from any role as a surrogate marker, AS is an important determinant of pulse pressure, left ventricular function and coronary artery perfusion pressure. Proximal elastic arteries and peripheral muscular arteries respond differently to aging and to medication. Endogenous human growth hormone (hGH), secreted by the anterior pituitary, peaks during early adulthood, declining at 14% per decade. Levels of insulin-like growth factor-I (IGF-I) are at their peak during late adolescence and decline throughout adulthood, mirror imaging GH. Arterial endothelial dysfunction, an accepted cause of increased APWV in GH defi ciency (GHD) is reversed by recombinant human (rh) GH therapy, favorably infl uencing the risk for atherogenesis. APWV is a noninvasive method for measuring atherosclerotic and hypertensive vascular changes increases with age and atherosclerosis leading to increased systolic blood pressure and increased left ventricular hypertrophy. Aerobic exercise training increases arterial compliance and reduces systolic blood pressure. Whole body arterial compliance is lowered in strength-trained individuals. Homocysteine and C-reactive protein are two infl ammatory markers directly linked with arterial endothelial dysfunction. Reviews of GH in the somatopause have not been favorable and side effects of treatment have marred its use except in classical GHD. Is it possible that we should be assessing the combined effects of therapy with rhGH and rhIGF-I? Only multiple intervention studies will provide the answer.
Introduction
Arterial distensibility and arterial compliance decrease with age and atherosclerosis leading to increased systolic blood pressure (SBP) and a widening of the pulse pressure (PP), resulting in left ventricular hypertrophy, a risk factor for cardiovascular disease (CVD) (Laogun and Gosling 1982; Riley et al 1986) .
Early changes in vascular properties precede the development of coronary artery disease (CAD) and hypertensive heart disease (Cohn et al 1995) . Arterial pulse wave velocity (APWV) and compliance alterations occur early in the course of essential hypertension in relation to other CVD risk factors (Brinton et al 1996) . Physical properties of the vasculature require a measurement of the distending force (ie, BP), using pressure transducers at relevant sites (Asmar et al 1995) . The form of the pulse wave through the walls of the blood vessels is affected by the mechanical properties of the vessels. Pulse-wave augmentation results from refl ections of the pulse wave at distal sites (such as bifurcations), such that the forward wave and refl ected wave superimpose producing the typical arterial pulse wave, which differs at different sites (O'Rourke 1999) . The PWV and the amplitude of refl ected waves are increased in stiffer arteries, and are reduced with increased arterial compliance (O'Rourke et al 2001) . These features are dependent on a number of hemodynamic variables, including heart rate and PP (Wilkinson et al 2002a) . Therefore, measurements of augmentation are generally corrected for PP and expressed as an "augmentation index" (AI x ). These measurements are also affected by vasoactive drugs (O'Rourke 1992; Kelly et al 2001; Wilkinson et al 2001a) and by insulin (Westerbacka et al 1999) and are sensitive to inhibition of nitric oxide synthase (Kinlay et al 2001; Stewart et al 2003) . The application of these measurements in concert with vasodilators has been proposed as an alternative approach for the measurement of vascular function (Wilkinson et al 2002b) .
Arterial pulse wave velocity
Measurement of arterial wave propagation as an index of vascular stiffness and vascular health dates back to the early part of the last century (Bramwell and Hill 1922) .
The arrival of the pulse wave at two different arterial sites is timed, and from estimates of the length of blood vessels between these sites (by measuring the distances at overlying skin sites), the velocity of this wave is calculated in m.s −1 (O'Rourke 1999; Lehmann 1999; Wilkinson et al 1999) . Subtleties come in correctly estimating the intervening distances. This provides a reliable measure of arterial stiffness; at a given blood pressure, the stiffer the vessel, the less time it takes for the pulse wave to travel the length of the vessel. The APWV, especially of the aorta, has emerged as an important independent predictor of cardiovascular events. APWV increases with stiffness and is defi ned by the Moens-Korteweg equation, PWV = √(Eh/2PR), where E is Young's modulus of the arterial wall, h is wall thickness, R is arterial radius at the end of diastole, and P is blood density (Lehmann 1999) . The time delay between the arrival of a predefi ned part of the pulse wave, such as the foot, at two points is obtained either by simultaneous measurement, or by gating to the peak of the R-wave of the ECG. The distance travelled by the pulse wave is measured over the body surface and APWV is then calculated as distance divided by time (m.s ) and depends on anatomical variation. The abdominal aorta tends to become more tortuous with age potentially leading to an underestimation of APWV (Wenn and Newman 1990) . APWs can also be detected by using Doppler ultrasound (Sutton-Tyrrell et al 2001) or applanation tonometry (Wilkinson et al 1998b) where the pressure within a small micromanometer fl attened against an artery equates to the pressure within the artery. Increases in distending pressure increase APWV (Bramwell and Hill 1922) . Therefore, account should be taken of the level of BP in studies that use APWV as a marker of cardiovascular risk.
An increase in HR of 40 beats per minute was shown to increase APWV by Ͼ1 m/s (Lantelme et al 2002) . Also acute increases in heart rate (HR) markedly lower arterial distensibility, occurring in both large and middle-size muscular arteries within the range of "normal" HR values (Giannattasio et al 2003) . Raised APWV occurs with a range of established cardiovascular risk factors (Lehmann et al 1998) including age (Bramwell et al 1923; Vaitkevicius et al 1993) , hypercholesterolemia (Lehmann et al 1992a) , type II diabetes mellitus (DM) (Lehmann et al 1992b) , and sedentary lifestyle (Vaitkevicius et al 1993) . In hypertension, carotid-femoral APWV is an independent predictor of both cardiovascular and all-cause mortality (Laurent et al 2001) . The odds ratio for a 5 m.s −1 (a relatively large change in PWV) increment in PWV was 1.34 for all-cause mortality and 1.51 for cardiovascular mortality. In contrast, PP was independently related to all-cause mortality but only marginally related to cardiovascular mortality, indicating that specifi c assessment of arterial stiffness, with APWV, may be of greater value in the evaluation of risk. APWV ranged from 9 to 13 m.s
, whereas recently quoted values of carotid-femoral PWV in healthy individuals with average ages of 24 to 62 years ranged from around 6 to 10 m.s −1 (O'Rourke et al 2002) . In hypertensive subjects without a history of overt cardiovascular disease APWV also predicts the occurrence of cardiovascular events independently of classic risk factors (Boutouyrie et al 2002) . Aortic APWV Ͼ13 m.s −1 is a particularly strong predictor of cardiovascular mortality in hypertension (Blacher et al 1999a) . Carotid-femoral APWV signifi cantly increases at a faster rate in treated hypertensives than in normotensive controls, although where BP was well controlled APWV progression was attenuated (Benetos et al 2002) . Aortic APWV, assessed by using Doppler fl ow recordings, independently predicts mortality in patients with endstage renal failure (ESRF), a population with a particularly high rate of cardiovascular disease (Blacher et al 1999b; Safar et al 2002) . The benefi t associated with BP control in ESRF, by the use of anti-hypertensives, was independently related to change in aortic APWV, such that a reduction in APWV of 1 m.s −1 was associated with a relative risk of 0.71 for all-cause mortality (Guerin et al 2001) .
The mechanisms of arterial stiffness
Windkessel theory treats the circulation as a central elastic reservoir (the large arteries), into which the heart pumps, and from which blood travels to the tissues through relatively nonelastic conduits (Oliver and Webb 2003) . The elasticity of the proximal large arteries is the result of the high elastin to collagen ratio in their walls, which progressively declines toward the periphery. The increase in arterial stiffness that occurs with age (Hallock and Benson 1937) is the result of progressive elastic fi bre degeneration (Avolio et al 1998) . The aorta and its major branches are large arteries, which can be differentiated from the more muscular conduit arteries, such as the brachial and radial arteries. The elasticity of a given arterial segment is not constant but instead depends on its distending pressure (Hallock and Benson 1937; Greenfi eld and Patel 1962) . As distending pressure increases, there is greater recruitment of relatively inelastic collagen fi bres and, consequently, a reduction in elasticity (Bank et al 1996) . In addition to collagen and elastin, the endothelium (Wilkinson et al 2002a) and arterial wall smooth muscle bulk and tone (Bank et al 1999) also infl uence elasticity. A number of genetic infl uences on arterial stiffness have also been identifi ed. Polymorphic variation in the fi brillin-1 receptor (Medley et al 2002) , angiotensin II type-1 receptor and endothelin receptor (Lajemi et al 2001a) genes are related to stiffness. The angiotensin-converting enzyme (ACE) I/D polymorphism has been associated with stiffness (Balkestein et al 2001) , but not consistently (Lajemi et al 2001b) . As a consequence of differing elastic qualities and wave refl ection, the shape of the arterial waveform varies throughout the arterial tree. In healthy, relatively young subjects, whereas mean arterial pressure (MAP) declines in the peripheral circulation, SBP and PP are amplifi ed (Kroeker and Wood 1955) . This amplifi cation is exaggerated during exercise (Rowell et al 1968) but reduces with increasing age (Wilkinson et al 2001) . APWV in the brachial artery has been shown to increase with age, indicative of worsening arterial compliance (Avolio et al 1983) . However, brachial artery PWV (baPWV) has been reported to change less with age than APWV in the aorta or lower limb arteries. In contrast, the assessment of distensibility using APWV is indirect and potentially affected by changes in blood fl ow and MAP that refl ect changes in more distal resistance vessels (Nichols and O'Rourke 1998) . Atherosclerosis, hypertension, and diabetes produce macro-and micro-vascular changes that are refl ected in vascular function and physical properties before the development of overt clinical disease (Berenson et al 1992) . Endothelial cells continuously release nitric oxide (NO), which is synthesized by the endothelial isoform of NO synthase (NOS-III) (Moncada et al 1991; Förstermann et al 1993) . NOS-III activity is stimulated by chemical agonists such as serotonin, acetylcholine (ACh) and bradykinin (Furchgott 1984; Cocks et al 1985; Newby and Henderson 1990) and by fl ow-induced shear forces on the endothelial cell wall (Pohl et al 1986; Busse and Pohl 1993; Meredith et al 1996) . Endothelium-derived NO diffuses toward the underlying vascular smooth muscle, producing relaxation. The vascular endothelium, therefore, plays a central role in the modulation of arterial smooth muscle tone and thus infl uences large-artery distensibility and the mechanical performance of the cardiovascular system (Ramsey et al 1995) . By improving arterial elasticity, endothelium-derived NO reduces the arterial wave refl ection and reduces left ventricular work and the pulse pressure within the aorta. In addition, exogenous acetylcholine and glyceryl trinitrate (GTN) both increase arterial distensibility, the former mainly through NO production. This may help explain why conditions that exhibit endothelial dysfunction are also associated with increased arterial stiffness. Therefore, reversal of endothelial dysfunction or drugs that are large-artery vasorelaxants may be effective in reducing large-artery stiffness in humans, and thus cardiovascular risk. GTN reduces brachial artery stiffness and decreases wave refl ection (Yaginuma et al 1986) . Moreover, drugs that stimulate endothelial NO release, such as ACh, also reduce muscular artery stiffness in vivo (Ramsey et al 1995; Joannides et al 1997) .
Specifi c studies in exercise
Changes in APWV in dynamic exercise in normal individuals, may provide a reference point against which to compare the effect of disease states and the basis for evaluation of their component mechanisms (Naka et al 2003) . Aerobic exercise training increases arterial compliance and reduces SBP and in cross-sectional studies, aerobically trained athletes have a higher arterial compliance than sedentary individuals (Mohiaddin et al 1989; Kingwell et al 1995; Vaitkevicius et al 1993) . Hammer throwers recorded signifi cantly higher compliance in the radial artery of the dominant arm relative to both the contra-lateral arm and to an inactive control group (Giannattasio et al 1992) . This could be explained by the dynamic nature of the action. A single bout of cycling exercise increased whole body arterial compliance by mechanisms suggesting vasodilation. In exercising muscles, factors including local increases in temperature, carbon dioxide, acidity, adenosine, NO and magnesium and potassium ions may all contribute to local vasodilation (Kingwell et al 1997a) . Four weeks of cycle training, in sedentary individuals, significantly increased forearm blood flow and blood viscosity, suggesting an increased basal production of nitric oxide from the forearm. The elevated shear stress in this vascular bed may contribute to endothelial adaptation (Kingwell et al 1997b) . Both the proximal aorta and the leg arteries were significantly stiffer and contributed to significantly higher aortic characteristic impedance in strength-trained athletes (Bertovic et al 1999) . However, large-artery stiffening associated with isolated systolic hypertension (ISH) is resistant to modification through short-term aerobic training (Ferrier et al 2001) . In subjects 70 to 100 years old, aortic APWV was a strong, independent significant predictor of cardiovascular death, whereas systolic blood pressure or pulse pressure was not (Meaume et al 2001) . GTN, an exogenous NO donor significantly increased brachial artery area and compliance and significantly decreased pulse wave velocity (Kinlay et al 2001) . In contrast to the beneficial effect of regular aerobic exercise, resistance training does not exert beneficial influences on arterial wall buffering functions (Miyachi et al 2003) . However, several months of resistance training "reduced" central arterial compliance in healthy men (Miyachi et al 2004) . The 3-hydroxyl-3-methyl coenzyme A reductase inhibitors (statins), significantly reduced total and low-density lipoprotein cholesterol and triglyceride levels and increased high density lipoprotein cholesterol and significantly lowered APWV (Ferrier et al 2002) . Atorvastatin significantly reduced arterial stiffness in patients with rheumatoid arthritis, possibly through an anti-infl ammatory action (Van Doornum et al 2004) . Age, blood pressure, body mass index (BMI), triglycerides, blood glucose and uric acid were shown to be significant variables for baPWV in both genders (Tomiyama et al 2003) . Central aortic stiffness would appear to be the initial main site for promotion of the development of coronary atherosclerosis and ischemic heart disease (McLeod et al 2004) .
Physiology of growth hormone (GH)
The ability of the somatotroph cells in the anterior pituitary to synthesize and secrete the polypeptide, human growth hormone (hGH) are determined by a gene called the Prophet of Pit-1 (PROP1). When GH is translated, 70%-80% is secreted as a 191-amino-acid, 4-helix bundle protein and 20%-30% as a less abundant 176-amino-acid form (Baumann 1991) (Figure 1 ). Hypothalamic-releasing and hypothalamic-inhibiting hormones acting via the hypophysial portal system control the secretion of GH, which is secreted into the circulation (Melmed 2006) .
In healthy persons, the GH level is usually Ͻ0.2 μg.L −1 throughout most of the day. There are approximately 10-12 intermittent bursts in a 24-hour period, mostly at night, when the level can rise to 30 μg.L −1 (Melmed 2006) . GH secretion declines at 14% per decade from the age of 20 years (Iranmanesh et al 1991) . GH action is mediated by a GH receptor, which is expressed mainly in the liver and is composed of dimers that change conformation when occupied by a GH ligand (Brown et al 2005) .
Cleavage of the GH receptor provides a circulating GH binding protein (GHBP), prolonging the half-life and mediating the transport of GH. Growth hormone activates the growth hormone receptor, to which the intracellular Janus kinase 2 (JAK2) tyrosine kinase binds. Both the receptor and JAK2 protein are phosphorylated, and signal transducers and activators of transcription (STAT) proteins bind to this complex. STAT proteins are then phosphorylated and translocated to the nucleus, which initiates transcription of growth hormone target proteins (Argetsinger et al 1993) .
Intracellular GH signalling is suppressed by suppressors of cytokine signalling. GH induces the synthesis of Figure 1 The structure of human growth hormone. Human growth hormone in its correct 22-kD-hGH form. Three-dimensional structure, generated from the protein data base SWISS PROT. Structural data supplied with the help of the program RasMol. The n-terminal amino acid is at the bottom right hand corner. The disulphide bridges make the molecule a 3 dimensional structure (the sequence range is missing on the 20 kDa hGH variant).
APWV, infl ammatory markers, GH and IGF states, cardiovascular and cerebrovascular disease peripheral insulin-like growth factor I (IGF-I) (Le Roith et al 2001) and endocrine, autocrine and paracrine IGF-I induces cell proliferation and is thought to inhibit apoptosis (O'Reilly et al 2006). IGF-binding proteins (IGFBP)
and their proteases regulate the access of ligands to the IGF-I receptor affecting its action. Levels of IGF-I are at their peak during late adolescence and decline throughout adulthood, mirror imaging GH and are determined by sex and genetic factors (Milani et al 2004) . IGF-I levels refl ect the secretory activity of growth hormone and is a marker for identifi cation of GH-defi ciency (GHD), or excess (Mauras and Haymond 2005) . The production of IGF-I is suppressed in malnourished patients, as well as in certain disease states, such as liver disease, hypothyroidism, or poorly controlled diabetes.
In conjunction with GH, IGF-I has varying differential effects on protein, glucose, lipid and calcium metabolism and therefore body composition (Mauras et al 2000) . Direct effects result from the interaction of GH with its specifi c receptors on target cells. In the adipocyte, GH stimulates the cell to break down triglyceride and suppresses its ability to uptake and accumulate circulating lipids. Indirect effects are mediated primarily by IGF-I.
Little is known about the expression of skeletal musclespecifi c isoforms of IGF-I gene in response to exercise in humans, nor the infl uence of age and physical training status. A single bout of isometric exercise stimulated the expression of mRNA for the IGF-I splice variants IGF-IEa and IGF-IEc (mechano growth factor [MGF]) within 2.5 hours, which lasts for at least 2 days after exercise (Greig et al 2006) .
Gh defi ciency (GHD)
The therapeutic indications for recombinant human growth hormone (rhGH) in the UK are controlled by the National Institute for Clinical Excellence guidelines (NICE 2003) , which has very strict guidelines and has recommended treatment with rhGH for children with:
• Growth disturbance in short children born small for gestational age • Proven GH defi ciency • Gonadal dysgenesis (Turner's syndrome) • Prader-Willi syndrome • Chronic renal insuffi ciency before puberty (renal function decreased to less than 50%). Treatment should be initiated and monitored by a pediatrician with expertise in managing GH disorders; treatment can be continued under a shared-care protocol by a general practitioner. Treatment should be discontinued if the response is poor (ie, an increase in growth velocity of less than 50% from baseline) in the fi rst year of therapy. In children with chronic renal insuffi ciency, treatment should be stopped after renal transplantation and not restarted for at least a year. NICE (2003) has recommended rhGH in adults only if the following three criteria are fulfi lled:
• Severe GH defi ciency, established by an appropriate method • Impaired quality of life, measured by means of a specifi c questionnaire • Already receiving treatment for another pituitary hormone defi ciency. Treatment should be discontinued if the quality of life has not improved suffi ciently by nine months. Severe GHD developing after linear growth is complete but before the age of 25 years should be treated with rhGH; treatment should continue until adult peak bone mass has been achieved. Treatment for adult-onset GH (A-OGH) defi ciency should be stopped only when the patient and the patient's physician consider it appropriate. Treatment with somatropin should be initiated and managed by a physician with expertise in GH disorders; maintenance treatment can be prescribed in the community under a shared-care protocol (British National Formulary 2008) . A-OGH defi cient individuals are overweight, with reduced lean body mass (LBM) (Salomon et al 1989; Amato et al 1993; Beshyah et al 1995) and increased fat mass (FM), especially abdominal adiposity (Salomon et al 1989; Bengtsson et al 1993; Amato et al 1993; Beshyah et al 1995; Snel et al 1995) . They have reduced total body water (Black et al 1972) and reduced bone mass (Kaufman et al 1992; O'Halloran et al 1993; Holmes et al 1994) . There is also reduced strength and exercise capacity (Cuneo et al 1990 (Cuneo et al , 1991a (Cuneo et al , 1991b and reduced cardiac performance and an altered substrate metabolism (Binnerts et al 1992; Fowelin et al 1993; Russell-Jones et al 1993; O'Neal et al 1994; Hew et al 1996) . This leads to an abnormal lipid profi le (Cuneo et al 1993; Rosen et al 1993; De Boer et al 1994; Attanasio et al 1997) which can predispose to the development of cardiovascular disease. A-OGH defi ciency reduces psychological well-being and quality of life (QoL) (Stabler et al 1992; Rosen et al 1994) . The use of rhGH is currently being used successfully to treat this defi ciency.
GH excess (acromegaly)
GH excess results in the clinical condition known as acromegaly. This condition is presented as a consequence of a pituitary tumor characterized by a multitude of signs and symptoms. Pituitary tumors account for approximately 15% of primary intracranial tumors (Melmed 2006) . Acromegalics have an increased risk of DM, hypertension and premature mortality due to CVD (Bengtsson et al 1993) .
The most common side effects following administration arise from sodium and water retention.
Weight gain, dependent edema, a sensation of tightness in the hands and feet, or carpal tunnel syndrome; can frequently occur within days (Hoffman et al 1996) .
Arthralgia (joint pain), involving small or large joints can occur, but there is usually no evidence of effusion, infl ammation, or X-ray changes (Salomon et al 1989) . Muscle pains can also occur. GH administration is documented to result in hyperinsulinemia (Hussain et al 1993) which may increase the risk of cardiovascular complications. GH-induced hypertension (Salomon et al 1989) and atrial fi brillation (Bengtsson et al 1993) have both been reported, but are rare. There have also been reports of cerebral side effects, such as encephalocele (Salomon et al 1989) and headache with tinnitus (Bengtsson et al 1993) and benign intra-cranial hypertension (Malozowski et al 1993) .
Cessation of GH therapy is associated with regression of side effects in most cases (Malozowski et al 1993) .
APWV in pathological GH states
The potential mechanisms accounting for this abnormality may result from a direct IGF-I mediated effect via increased production of NO. Qualitative alterations in lipoproteins have been described in GHD adults (O'Neal et al 1996) , resulting in the generation of an atherogenic lipoprotein phenotype, which would contribute to endothelial dysfunction.
Growth hormone defi ciency (GHD)
Increased oxidative stress exists in GHD adults, which may be a factor in atherogenesis and reduced by GH therapy's effects on oxidative stress (Evans et al 2000) . Endothelial dysfunction exists in GHD adults (Evans et al 1999) , which is reversible with GH replacement (Pfeifer et al 1999) . An impaired endothelial-dependent dilatation (EDD) response was documented in GHD adults, which significantly improved after GH treatment.
Patients with GHD, with increased risk of vascular disease, have impaired endothelial function and increased AI x compared with controls. Replacement of GH resulted in improvement of both endothelial function and AI x , without changing BP (Smith et al 2002) .
Replacement of GH for 3 months corrected endothelial dysfunction in patents with chronic heart failure (Napoli et al 2002) .
Renal failure induces GH resistance at the receptor and post-receptor level, with concomitant endothelial dysfunction, which can be overcome by replacement of GH (Lilien et al 2004) .
Growth hormone excess
Acromegaly is associated with changes in the central arterial pressure waveform, suggesting large artery stiffening. This may have important implications for cardiac morphology and performance as well as increasing the susceptibility to atheromatous disease.
Large artery stiffness is reduced in "cured" acromegaly (GH Ͻ 2.5 mU.L −1
) and partially reversed after pharmacological treatment of active disease (Smith et al 2003) .
GH and infl ammatory markers of CVD
Human peripheral blood T cells, B cells, natural killer (NK) cells, and monocytes express IGF-I receptors (Wit et al 1993) . Administration of either GH or IGF-I can reverse the immunodefi ciency of Snell dwarf mice (Van Buul-Offers et al 1986) . GH replacement induced a signifi cant overall increase in the percent specifi c lysis of K562 tumor target cells, in healthy adults (Crist and Kraner 1990) . NK activity was signifi cantly increased throughout the six weeks period of administration. In vitro studies, using human lymphocytes indicate that GH is important for the development of the immune system (Wit et al 1993) . However, pre-operative administration of GH did not alter C-reactive protein (CRP), serum amyloid A (SAA) or interleukin-6 (IL-6, an infl ammatory cytokine) release (Mealy et al 1998) . Homocysteine (HCY) concentration has been established as an independent risk factor for atherosclerosis (Eichinger et al 1998; Stehouwer and Jakobs 1998) . CRP and IL-6 levels and central fat decreased signifi cantly in rhGH recipients in GHD after 18 months. Lipoprotein(a) and glucose levels signifi cantly increased, without affecting lipid levels (Sesmilo et al 2000) . HCY impairs vascular endothelial function through signifi cant reduction of NO production. This appears to potentiate oxidative stress and atherogenic development (van Guldener and Stehouwer 2000) . HCY levels were not signifi cantly elevated in GHD adults and HCY was considered to be unlikely to be a major risk factor for vascular disease, if there are no other risk factors present (Abdu et al 2001) . Pegvisomant (GH receptor antagonist) did not induce signifi cant acute changes in the major risk markers for CVD, in apparently healthy abdominally obese men (Muller et al 2001) . This suggested that the secondary APWV, infl ammatory markers, GH and IGF states, cardiovascular and cerebrovascular disease metabolic changes, eg, infl ammatory factors, which develop as a result of long-standing GHD are of primary importance in the pathogenesis of atherosclerosis in patients with GHD. Patients with active acromegaly have signifi cantly lower CRP and signifi cantly higher insulin levels than healthy controls and administration of pegvisomant signifi cantly increased CRP to normal levels (Sesmilo et al 2002) . GH secretory status may be an important determinant of serum CRP levels, but the mechanism and signifi cance of this fi nding is as yet unknown. Infl ammatory markers are predictive of atherosclerosis and cardiovascular events (Ridker et al 2002; Danesh et al 2004) . The metabolic syndrome (MS) is correlated with elevated CRP and a predictor of coronary heart disease and DM (Sattar et al 2003) . IL-6 concentrations were signifi cantly increased in GHD, compared to BMI-matched and nonobese controls, respectively (Leonsson et al 2003) . CRP significantly increased in patients compared to nonobese controls, but not signifi cantly different compared to BMI-matched controls. Age, LDL-cholesterol, and IL-6 were positively correlated, and IGF-I was negatively correlated to arterial intima-media thickness (IMT) in the patient group, but only age and IL-6 were independently related to IMT.
Potential mechanisms
Oxidative stress represents a mechanism leading to the destruction of neuronal and vascular cells.
Oxidative stress occurs as a result of the production of free radicals or reactive oxygen species (ROS). ROS consist of entities including the superoxide anion, hydrogen peroxide, superoxide anion, NO, and peroxynitrite. The production of ROS, such as peroxynitrite and NO, can lead to cell injury through cell membrane lipid destruction and cleavage of DNA (Vincent and Maiese 1999) . Production of excess ROS can result in the peroxidation of docosahexenoic acid (DHA), a precursor of neuroprotective docosanoids (Mukherjee et al 2004) . DHA is a fatty acid released from membrane phospholipids and is derived from dietary essential fatty acids. It is involved in memory formation, excitable membrane function, photoreceptor cell biogenesis and function and neuronal signaling. DHA may have a role in modulating IGF-I binding in retinal cells (Yorek et al 1989) . Neuroprotectin D1 (NPD1) is a DHA-derived mediator that protects the central nervous system (brain and retina) against cell injury-induced oxidative stress, in cerebral ischemiareperfusion. It up-regulates the anti-apoptotic Bcl-2 proteins, Bcl-2, and Bclxl and decreases pro-apoptotic Bax and Bad expression (Bazan 2005) .
IGF-I also blocks Bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signalling in cerebellar granule neurons (Linseman et al 2002) .
Dorsal root ganglia (DRG) neurons express IGF-I receptors (IGF-IR), and IGF-I activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. High glucose exposure induces apoptosis, which is inhibited by IGF-I through the PI3K/Akt pathway. IGF-I stimulation of the PI3K/Akt pathway phosphorylates three known Akt effectors: the survival transcription factor cyclic AMP response element binding protein (CREB) and the pro-apoptotic effector proteins glycogen synthase kinase-3beta (GSK-3beta) and forkhead (FKHR). IGF-I regulates survival at the nuclear level through accumulation of phospho-Akt in DRG neuronal nuclei, increased CREB-mediated transcription, and nuclear exclusion of FKHR. High glucose levels increase expression of the pro-apoptotic Bcl protein Bim (a transcriptional target of FKHR). High glucose also induces loss of the initiator caspase-9 and increases caspase-3 cleavage, effects blocked by IGF-I, suggesting that IGF-I prevents apoptosis in DRG neurons by regulating PI3K/Akt pathway effectors, including GSK-3beta, CREB, and FKHR, and by blocking caspase activation (Leinninger et al 2004) .
The unique role of IGF-IR in maintaining the balance of death and survival in foetal brown adipocytes, in IGF-IR defi ciency has been demonstrated (Valverde et al 2004) .
A vascular protective role for IGF-I has been suggested because of its ability to stimulate NO production from endothelial and vascular smooth muscle cells. IGF-I probably plays a role in aging, atherosclerosis and cerebrovascular disease, cognitive decline, and dementia. In cross sectional studies, low IGF-I levels have been associated with an unfavorable profile of CVD risk factors, such as atherosclerosis, abnormal lipoprotein levels and hypertension, while in prospective studies, lower IGF-I levels predict future development of ischemic heart disease. The fall in the levels of GH (Iranmanesh et al 1991) and IGF-I (Milani et al 2004) with aging correlates with cognitive decline and it has been suggested that IGF-I plays a role in the development of dementia. IGF-I is highly expressed within the brain and is essential for normal brain development. IGF-I has anti-apoptotic and neuroprotective effects and promotes projection neuron growth, dendritic arborization and synaptogenesis (Ceda et al 2005) .
Conclusion
Collectively, these data are consistent with a causal link between the age-related decline in GH and IGF-I levels and cardiovascular and cerebrovascular disease in senescence. Research into the benefi ts of replacement hormone therapy is still in its infancy. It was only three decades ago that rhGH became available and signifi cant progress into the somatopause and related pathologies has occurred. Could the future propose the concomitant use of rhGH and rhIGF as has been used in certain refractory cases of diabetes and GH resistance (Mauras and Haymond 2005) ? The reviews of rhGH replacement in obesity have not been revolutionary (Liu et al 2007) . It might be expedient to research the combination of rhGH and rhIGF in the variety of physiological GHD states to determine any benefi cial effects. After all, it wasn't until 1999 that hypothyroidism was identifi ed as being more appropriately treated with tri-iodothyronine (T 3 ) and tetra-iodothyronine (T 4 ), than T 4 alone (Bunevicius et al 1999) .
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